Core Viewpoint - Compugen Ltd. has initiated a Phase 1 clinical trial for COM503, a potential first-in-class antibody targeting IL-18 binding protein, licensed to Gilead, marking a significant advancement in cancer immunotherapy [1][7]. Group 1: Clinical Trial Details - The Phase 1 trial is a multi-center dose escalation and expansion study aimed at evaluating the safety, tolerability, and pharmacokinetics of COM503 both as a monotherapy and in combination with Gilead's anti-PD1 antibody, zimberelimab, in patients with advanced solid tumors [2][4]. - The trial commenced in the fourth quarter of 2024 as planned, with the primary objectives including assessing safety and identifying the maximum tolerated dose [4]. Group 2: Mechanism of Action - COM503 is designed to block the endogenous IL-18 binding protein, which inhibits the anti-tumor activity of IL-18, thereby potentially enhancing local immune responses against tumors [3][5]. - The unique mechanism of action of COM503 offers a novel treatment option for cancer patients, as noted by clinical researchers involved in the trial [3]. Group 3: Licensing Agreement and Financials - In December 2023, Compugen and Gilead entered into a licensing agreement granting Gilead exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including COM503 [5]. - Compugen received an upfront payment of $60 million and an additional $30 million upon IND clearance, with potential future milestone payments totaling up to $758 million, leading to a total deal value of up to $848 million [5]. Group 4: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery platform, Unigen™, to identify new drug targets for cancer immunotherapies [6][8]. - The company has two other proprietary product candidates in Phase 1 development, COM701 and COM902, targeting different mechanisms in solid tumors [6].

Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitors HOLON, Israel, Nov. 27, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants ...

Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this drug developer would post a loss of $0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%. Over the last four quarters, the company has surpa ...

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commerc ...

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 18, 2024 [1] - The event will be accessible via a live webcast on the company's Investor Relations website, with a replay available afterward [2] Company Overview - Compugen utilizes its predictive computational discovery platform, UnigenTM, to identify new drug targets and biological pathways for cancer immunotherapies [3] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - Compugen's pipeline includes early-stage immuno-oncology programs, with COM503, an anti-IL-18 binding protein antibody, having received IND clearance from the FDA and licensed to Gilead [3] - Compugen is headquartered in Israel and has offices in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]

HOLON, ISRAEL, Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data an ...

We expect investors to focus on Compugen Ltd.’s (CGEN) progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteCompugen’s top line currently comprises revenues recognized from its license agreement with Gilead Sciences (GILD) and AstraZeneca. The company reported $6.7 million in revenues in the last reported quarter, comprising an upfro ...

Compugen (CGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing e ...

HOLON, Israel, Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Monday, September 9, 2024, 7:00 AM ET for 30 days. About Compugen Compugen is a clinical ...